Navigation Links
Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
Date:9/1/2008

Could Be Life-Changing for Stroke, Traumatic Brain Injury, Alzheimer's

Patients

MORGANTOWN, W.Va., Sept. 1 /PRNewswire-USNewswire/ -- Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI -- administered 24 hours after stroke can rescue and repair brain tissue. These findings are markedly advanced compared to current stroke treatments that must be administered within three hours and are unable to repair damaged brain tissue.

In an article to be published in the September 3 issue of the Proceedings of the National Academy of Sciences (PNAS), BRNI Scientific Director and Toyota Chair Daniel Alkon, M.D. and Professor Miao-Kun Sun, PhD describe how this Alzheimer's candidate drug repairs the brain and improves memory.

"Today's stroke patient has precious minutes to receive care without suffering irreversible damage or death. One of the greatest challenges in modern medical practice is finding an effective treatment that extends that treatment time and repairs damage," said BRNI Scientific Director Daniel Alkon, M.D. "Bryostatin could be an answer."

Bryostatin could be life changing for millions of Americans who suffer neurological conditions -- from Alzheimer's disease to stroke. Each year in the United States, there are more than 780,000 strokes. It is the third leading cause of death in the country and the most common cause of long-term disability in developed countries. Nearly three-quarters of all strokes occur in people over the age of 65 and the risk of having a stroke more than doubles each decade after the age of 55.

"We're facing an aging Babyboomer population, an influx of 55-plus Americans, and treatment that is less time-restrictive and able to repair the brain if a stroke destroys tissue is urgently needed," said Alkon.

How Bryostatin Works

Stroke symptoms typically de
'/>"/>

SOURCE Blanchette Rockefeller Neurosciences Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
2. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
3. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
10. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
11. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire-FirstCall/--Formanyofthemillionsofhearingimpai...ated hearingloss ,theholidaysmaynotbeallthathappy,...cepresidentofHearUSA(Amex: EAR ),oneofAmerica,slar...eshavelinkedhearinglosstostress,frustration,andsoc...gatheringswithfamiliesandfriends,whenmanyofthosewi...
(Date:11/25/2009)...tlinker.comannouncesthatanewmarketresearchreportis...DevicesMarketAnalysisandForecaststo2015 ,, ht...ental-Devices-Market-Analysis-and-Forecasts-to-201...sisandForecaststo2015 ,, Summary ,, Thisre...tarelatingtotheUSdentaldevicesmarket.Italsooffersd...
(Date:11/25/2009)...all/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicec...ptivesurgicaltreatmentsforthespine,announcedtodayt...09,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfo...pany,sproductsandwillincludecommentsfrommanagement...nnumbersare1-877-407-4018fordomesticcallersand1-20...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3A Mediterranean Approach to Flavorful Living 56023 1A Mediterranean Approach to Flavorful Living 56023 2A Mediterranean Approach to Flavorful Living 56023 3Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 1Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 2Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 3Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 4eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2
...groups show dose-dependent PSA d... call to be held today at 8:30 A.M. Eastern time -...: MDVN ) today announced that its selective andro...ed serum levels of prostate specific,antigen (PSA)...rolled in,the first two dose groups of its ongoing...
...ustained virologic response in non-respond...results in line with previous studies of long-acti...th less frequent dosing -, - Final data from Phas..., Annual Meeting of the American Association for t... (AASLD) -, ROCKVILLE, Ma., Nov. 5 Human G...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
(Date:11/25/2009)...wswire-USNewswire/--WhenmostpeopleheartheacronymTM...ivepatientsthehelptheyneed.TMJstandsfortheTemporal...acts/connectswithyourskull(temporalbone). ,, Th...painwithchewing,clickingorpoppingofthejaw.Butmanyo...:headaches,fatigue,sleepdisturbances,irritability,...
(Date:11/25/2009)...5/PRNewswire-FirstCall/-- OnyxPharmaceuticals,Inc...sttwoinvestoreventsinDecember: ,, ASHBriefing... ,, Principalinvestigatorswilldiscussdatapresen...ctorymultiplemyeloma,asfeaturedatthe51stAmericanSo...NewOrleans,LA.Theteleconferencewillbeginat9:00a.m....
(Date:11/25/2009)...re/-SentinelleMedicalInc.,aleadingmanufacturerofbr...esasuiteofnewleadingedgeclinicalapplicationsonitsA...RadiologicalSocietyofNorthAmerica(RSNA)annualmeeti...applicationsleveragetheuniquehighqualityimagesgene...pportmultipleimagingmodalitiesformulti-parametrica...
(Date:11/25/2009).../PRNewswire-USNewswire/--AnarticlebyJanetWoodcock,...esearch,titled"ADifficultBalance-PainManagement,Dr...TheNewEnglandJournalofMedicine. ,, (Logo: http:...,, Inthearticle,WoodcockdiscussesFDAeffortstost...honeeditandmanagingtherisksposedbyvariousanalgesic...
(Date:11/25/2009)...ewswire/--TheBayAreaAirQualityManagementDistrictis...Air Alert forThursday,November26,2009whichban...el,bothindoorsandoutdoors. ,, "Cold,stillweathe...JackBroadbent,executiveofficeroftheAirDistrict."We...neighborsandfellowcommunitymembersthisThanksgiving...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...ore research is being published showing the benefi...l tolerated by most patients due to the aftertaste...hers at Banner now say they have developed a chewa...oft chewable shell that can be taken without water...
... medications available , one must also be wary of ...ng to the Drug Control Department, 63 batches of s...killers and cardiac medicines, are being sold in B... drug racket first came to light in May-end this y...
...n B9 has been known to help in the brain developme...e to this reason it is administered to pregnant wo...ngen University, Netherlands has proposed that thi... increased levels of homocysteine. This amino acid...
... Lancet investigated the efficacy of acupuncture c...puncture in patients with osteoarthritis of the kn...reat many types of patients with chronic pain. ...o the acupuncture group, second group with 76 pati...
...able to stop the geriatric population from falling...ntain their balance. The device is called Yak...e that conforms to the footwear and helps the peop...of the number of falls they have on wearing the de...
...rom peripheral arterial disease may lose their lim...s to attend to them. Research findings report that...r surgeons, report less number of cases where pati...ften the only symptom experienced is a recurring p...
Other Medicine News:
Hi-Top Post Op Shoe
EZY Close
Forefoot Reliever
Ultra 90 Fixed Plantar Fasciitis Splint
Medicine Products: